Biovica Q1: Completed Clinical Validation and Directed Issue (II)
Research Note
2020-08-27
13:32
Redeye comments further on the successful directed share issue, the clinical validation as well as the Q1 2020/21 report. We raise our base and bull cases by 15+ percent.
NE
Niklas Elmhammer
Disclosures and disclaimers